Replies to post #93200 on Anavex Life Sciences Corp (AVXL)

[McMagyar]

My other point is.. with ALL the possible indications upon which A2-73 may cause positive effect,
We have a drug which will DEMAND access and Value..

It adds up to Billions no matter how you slice it..
For longs it's time to stop writing calls..you win

[Amatuer17]

Rett is a rare disease so finding right patients at place is not an easy task. They need 60 patients and trial duration is 12 weeks (3 months)

This means - the end of the year timeline may prove to be optimistic - for this to happen - the last patient needs to be enrolled before Aug - give one month for topline result calculations/ preparation.

The trial has not started yet - assuming the trial starts by Mid-March and 1st patient is enrolled in April - they will need to enroll 12 patients per month

This number is high for a rare disease trial enrollment and is aggressive.
(They will also compete with other trials for patients)

So if we get topline results by end of year - it is very good sign.

We just need to confirm that protocol is approved and trial is registered and officially started.